2025-12-30 - Analysis Report
Okay, here's a breakdown of the provided data on Eli Lilly and Co. (LLY), incorporating analysis and comparisons.

**0) Overview**

First the numbers, then the analysis.

**1) Return Rate Comparison**

*   **Eli Lilly and Co. (LLY):** A pharmaceutical company focused on discovering, developing, and marketing medicines.
*   **LLY Cumulative Return:** 307.99%
*   **VOO (S&P 500) Cumulative Return:** 103.21%
*   **Divergence:**
    *   Current: 204.7
    *   Relative Divergence: 84.5

*   **Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 11.0%  | 76.1% | -17.0%  | -0.0   | 75.8   |
| 2016-2018  | 39.0%  | 68.9% | 24.0%   | -0.0   | 103.8  |
| 2017-2019  | 41.0%  | 68.9% | 19.0%   | 0.4    | 117.9  |
| 2018-2020  | 34.0%  | 79.8% | 10.0%   | 0.4    | 151.5  |
| 2019-2021  | 53.0%  | 79.8% | 7.0%    | 0.5    | 247.8  |
| 2020-2022  | 64.0%  | 79.8% | 65.0%   | 0.4    | 328.3  |
| 2021-2023  | 125.0% | 78.9% | 124.0%  | 0.2    | 523.0  |
| 2022-2024  | 134.0% | 81.2% | 113.0%  | 0.2    | 692.7  |
| 2023-2025  | 199.0% | 83.5% | 132.0%  | 0.2    | 967.0  |

**Analysis:**

*   **Outperformance:** LLY has significantly outperformed the S&P 500 (VOO) with a cumulative return nearly triple that of the index.
*   **Divergence:** The significant positive divergence indicates LLY's returns have strongly exceeded the S&P 500's, and the relative divergence of 84.5 suggests this outperformance is near the upper end of its historical range.
*   **Alpha:**  LLY's alpha is overwhelmingly positive, especially in recent years (2020-2025), indicating that the stock is generating excess returns compared to its benchmark. This is a strong positive signal.
*   **Beta:** The beta is generally low, fluctuating between 0.2-0.5 from 2017, suggesting that LLY is less volatile than the market. In 2015-2018, the beta was approximately 0. This indicates lower market risk.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) is increasing considerably.
*   **MDD:** The Maximum Drawdown (MDD) is high, staying within the 68.9-83.5% range. Investors should be wary of the MDD percentage, especially for the period of 2023-2025.
*   **Cap:** Market capitalization is growing.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 1077.75
*   **Last Market Data:** {'price': 1078.73, 'previousClose': 1077.75, 'change': 0.09}
*   **5-day SMA:** 1074.86
*   **20-day SMA:** 1040.49
*   **60-day SMA:** 952.21

**Analysis:**

*   **Uptrend:** The stock is trading above its 5-day, 20-day and 60-day moving averages, indicating an upward trend.
*   **Momentum:** The 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA, further confirming the bullish momentum. The increase in the 5 day SMA indicates the stock is rising, in contrast with the previous closing price.
*   **Recent Market Change:** The small change in the last market data indicates a relatively stable closing.

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 69.37
*   **PPO:** -0.0279
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent (20 days) relative divergence change:** 5.8 (+): 단기상승 (short-term increase)
*   **Expected Return:** 49.2% (over 2 years)

**Analysis:**

*   **High MRI:** The high MRI suggests the market conditions are generally favorable for investment in this stock.
*   **RSI:** The RSI is approaching overbought territory (above 70). While not definitively overbought yet, it warrants watching for a potential pullback.
*   **PPO:** The PPO is slightly negative, implying that LLY's short-term momentum is slightly lower than its long-term momentum.
*   **Hybrid Signal:** The hybrid signal recommends buying into the company at 100% of cash.
*   **Divergence Change:** The recent increase in relative divergence suggests that LLY has been recently outperforming its comparison (S&P 500)
*   **Strong Expected Return:** The high expected return indicates significant potential upside if held for the long term.

**4) Recent News & Significant Events**

*   **Stock Split Candidate:** Mention of LLY being a top stock split candidate could indicate expectations of continued growth and a desire to make the stock more accessible to retail investors.
*   **GLP-1 Pill Breakthroughs and Pricing:** News related to GLP-1 breakthroughs and pricing suggests that LLY's developments in this area (likely related to diabetes and weight loss) are significant drivers of attention and potential market impact.
*   **Price Slash on Zepbound:** The price cut on Zepbound might raise concerns about margin compression, but it could also increase market share and overall revenue.
*   **Rating Downgrade:** The mention of a rating downgrade suggests some analysts may have a more cautious outlook on the stock.
*   **Market Focus:** Being mentioned in broader market news indicates the stock is on investors' radars.

**Analysis:**

The news is a mix of positive and cautionary signals. The potential stock split, GLP-1 advancements, and broad market focus are positive. The price cut on Zepbound and the rating downgrade introduce some uncertainty. The GLP-1 medications are generating momentum, especially with weight-loss drugs.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.70)
*   **Opinions:** 27
*   **Target Price:**
    *   Average: 1093.22
    *   High: 1500.00
    *   Low: 770.00

**Analysis:**

*   The overall analyst sentiment is bullish, with a consensus rating of "Buy."
*   The average target price suggests a modest upside from the current price. However, the high target price indicates that some analysts are very optimistic about the stock's potential.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-10-30 | 6.22 | 17.60 B$     |
| 2025-08-07 | 6.30 | 15.56 B$     |
| 2025-05-01 | 3.07 | 12.73 B$     |
| 2024-10-30 | 1.08 | 11.44 B$     |
| 2025-10-30 | 1.08 | 11.44 B$     |

**Analysis:**

*   **Strong Growth:** Both EPS and revenue have shown significant growth over the past year. The EPS has experienced high growth in between 2025-05-01 and 2025-08-07.
*   **Consistency:** Earnings have generally exceeded expectations, further boosting investor confidence.
*   **Duplication:** The duplication in data should be noted.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $17.60B  | 82.91%        |
| 2025-06-30   | $15.56B  | 84.27%        |
| 2025-03-31   | $12.73B  | 82.53%        |
| 2024-12-31   | $13.53B  | 82.24%        |
| 2024-09-30   | $11.44B  | 81.02%        |

Capital and Profitability:

| Quarter      | Equity   | ROE    |
|--------------|----------|--------|
| 2025-09-30   | $23.79B  | 23.46% |
| 2025-06-30   | $18.27B  | 30.98% |
| 2025-03-31   | $15.76B  | 17.50% |
| 2024-12-31   | $14.19B  | 31.07% |
| 2024-09-30   | $14.24B  | 6.81%  |

**Analysis:**

*   **Revenue Growth:**  Consistent and strong revenue growth quarter-over-quarter.
*   **High Profit Margins:**  Extremely high and stable profit margins, indicating strong pricing power and efficient cost management.
*   **Increasing Equity:** The company's equity is steadily increasing, reflecting its financial health and growth.
*   **Strong ROE:** The Return on Equity (ROE) is very high, demonstrating the company's ability to generate profits from shareholder investments.

**7) Comprehensive Analysis**

Eli Lilly (LLY) presents a compelling investment case based on the provided data.

*   **Strong Performance:** LLY has significantly outperformed the S&P 500, driven by strong revenue and earnings growth.
*   **Positive Outlook:** Analyst sentiment is bullish, and the company is showing strong financial health.
*   **Growth Catalysts:** The company is benefiting from developments in GLP-1 drugs and other pharmaceutical advancements.
*   **Potential Risks:** The high MDD percentages, RSI approaching overbought and a recent rating downgrade suggest investors should be cautious.
*   **Recommendation:** The data suggests that LLY is a strong investment opportunity with significant growth potential. However, investors should carefully consider the risks associated with the company.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.